» Articles » PMID: 34224262

Mortality Among Persons Entering HIV Care Compared With the General U.S. Population : An Observational Study

Abstract

Background: Understanding advances in the care and treatment of adults with HIV as well as remaining gaps requires comparing differences in mortality between persons entering care for HIV and the general population.

Objective: To assess the extent to which mortality among persons entering HIV care in the United States is elevated over mortality among matched persons in the general U.S. population and trends in this difference over time.

Design: Observational cohort study.

Setting: Thirteen sites from the U.S. North American AIDS Cohort Collaboration on Research and Design.

Participants: 82 766 adults entering HIV clinical care between 1999 and 2017 and a subset of the U.S. population matched on calendar time, age, sex, race/ethnicity, and county using U.S. mortality and population data compiled by the National Center for Health Statistics.

Measurements: Five-year all-cause mortality, estimated using the Kaplan-Meier estimator of the survival function.

Results: Overall 5-year mortality among persons entering HIV care was 10.6%, and mortality among the matched U.S. population was 2.9%, for a difference of 7.7 (95% CI, 7.4 to 7.9) percentage points. This difference decreased over time, from 11.1 percentage points among those entering care between 1999 and 2004 to 2.7 percentage points among those entering care between 2011 and 2017.

Limitation: Matching on available covariates may have failed to account for differences in mortality that were due to sociodemographic factors rather than consequences of HIV infection and other modifiable factors.

Conclusion: Mortality among persons entering HIV care decreased dramatically between 1999 and 2017, although those entering care remained at modestly higher risk for death in the years after starting care than comparable persons in the general U.S. population.

Primary Funding Source: National Institutes of Health.

Citing Articles

Progress in Early Detection of HIV in Tajikistan.

Alaei K, Kwan B, Torabzadeh H, Akinwalere A, Saydamirovich S, Mohsinzoda G Viruses. 2024; 16(7).

PMID: 39066173 PMC: 11281724. DOI: 10.3390/v16071010.


Development of Anti-HIV Therapeutics: From Conventional Drug Discovery to Cutting-Edge Technology.

Sun Y, Wang L Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065738 PMC: 11280173. DOI: 10.3390/ph17070887.


Incidence of Colon Cancer Among Medicaid Beneficiaries With or Without Human Immunodeficiency Virus Under Comparable Colorectal Cancer Screening Patterns.

Rudolph J, Calkins K, Zhang X, Zhou Y, Pirsl F, Xu X Open Forum Infect Dis. 2024; 11(5):ofae246.

PMID: 38798894 PMC: 11127480. DOI: 10.1093/ofid/ofae246.


Projected Life Expectancy for Adolescents With HIV in the US.

Neilan A, Ufio O, Brenner I, Flanagan C, Shebl F, Hyle E JAMA Health Forum. 2024; 5(5):e240816.

PMID: 38728022 PMC: 11087843. DOI: 10.1001/jamahealthforum.2024.0816.


Improving Care for People Aging with HIV: A Collaborative Quality Improvement Approach.

Belanger D, Wikiera J, Albarran M, Zhu A, Fera N, Glassman R J Community Health. 2024; 49(6):1026-1032.

PMID: 38668811 PMC: 11412789. DOI: 10.1007/s10900-024-01362-5.


References
1.
Hartzler B, Dombrowski J, Crane H, Eron J, Geng E, Mathews W . Prevalence and Predictors of Substance Use Disorders Among HIV Care Enrollees in the United States. AIDS Behav. 2016; 21(4):1138-1148. PMC: 6089366. DOI: 10.1007/s10461-016-1584-6. View

2.
Althoff K, McGinnis K, Wyatt C, Freiberg M, Gilbert C, Oursler K . Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. Clin Infect Dis. 2014; 60(4):627-38. PMC: 4318916. DOI: 10.1093/cid/ciu869. View

3.
Samji H, Cescon A, Hogg R, Modur S, Althoff K, Buchacz K . Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013; 8(12):e81355. PMC: 3867319. DOI: 10.1371/journal.pone.0081355. View

4.
Althoff K, Gebo K, Moore R, Boyd C, Justice A, Wong C . Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. Lancet HIV. 2019; 6(2):e93-e104. PMC: 6589140. DOI: 10.1016/S2352-3018(18)30295-9. View

5.
Clotet B, Feinberg J, van Lunzen J, Khuong-Josses M, Antinori A, Dumitru I . Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014; 383(9936):2222-31. DOI: 10.1016/S0140-6736(14)60084-2. View